TAILORx: New Data on Cohort with Recurrence Score 26-100 Shows 93% Cancer-Free Rate at 5 Years
A new analysis from TAILORx, the largest ever breast cancer treatment trial, was published in the journal JAMA Oncology. It reveals the clinical outcomes with chemotherapy in a subset of 1,389 women with a high Recurrence Score (RS) of 26-100. The outcomes are similar to the B20 trial (Paik et al, JCO, 2006). The new data shows that the estimated rate of freedom from recurrence of breast cancer at a distant site was 93% at five years, an outcome much better than expected with endocrine therapy alone. The results were featured at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona.
This finding adds to the limited data on outcomes of patients with a high RS of 26-100, treated with taxane and/or anthracycline-containing chemotherapy regimens plus hormone therapy. It adds to the evidence base supporting the use of the Recurrence Score, a 21-tumor gene expression assay, to guide the use of adjuvant chemotherapy in early breast cancer.
TAILORx was designed and conducted by the ECOG-ACRIN Cancer Research Group with primary funding from the National Cancer Institute, part of the National Institutes of Health.
"The initial results of TAILORx gave clinicians high-quality data to inform personalized treatment recommendations for women," said lead author Joseph A. Sparano, M.D., associate director for clinical research at the Albert Einstein Cancer Center and Montefiore Health System in New York, and vice chair of the ECOG-ACRIN Cancer Research Group. "This new analysis provides the largest data set on outcomes in patients with early breast cancer and high Recurrence Score results. It confirms the importance of using the test to identify the minority of patients who will receive a significant benefit from adding adjuvant chemotherapy to endocrine therapy."